Q-omics provides the consensus-scored FSTL3 profile across patient tissues and cancer cell-line models. FSTL3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, FSTL3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, FSTL3 RNA expression shows 18,778 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, HNSC, and LSCC as cancer lineages where FSTL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FSTL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FSTL3 survival associations across molecular data types. FSTL3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FSTL3 RNA expression–survival associations across cancer types. High FSTL3 expression shows unfavorable associations in LUSC, MESO, COAD, OV, UCEC and HNSC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for FSTL3 RNA expression.
This table summarizes FSTL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FSTL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FSTL3 shows lower tumor expression in KICH and LUSC and higher tumor expression in HNSC, COAD, THCA and KIRC. The HNSC box plot shows higher FSTL3 RNA expression in tumor versus normal tissue (log2 FC = +3.556, t-test p < 0.001).
This table shows molecular features associated with FSTL3 in patient tissues and cancer cell lines. In patient samples, FSTL3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FSTL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
